ZEOX (Zeo ScientifiX) EBIT: $-3.81 Mil (TTM As of Apr. 2026)


ZEOX Zeo ScientifiX Inc ZEOX
50 GF Score
Price $1.75
GF Value $2.67
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Zeo ScientifiX EBIT?

Zeo ScientifiX ZEOX +2.94% 50 EBIT is $-3.81 Mil as of Apr. 2026. GuruFocus rates ZEOX with a GF Score™ of 50/100 and a GF Value™ of $2.67 (Possible Value Trap). The stock has 4 warning signs investors should review.

Zeo ScientifiX's earnings before interest and taxes (EBIT) for the three months ended in Apr. 2026 was $-0.13 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Apr. 2026 was $-3.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zeo ScientifiX's annualized ROC % for the quarter that ended in Apr. 2026 was -133.55%. Zeo ScientifiX's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -91.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -31.18%.

Zeo ScientifiX  (OTCPK:ZEOX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zeo ScientifiX's annualized ROC % for the quarter that ended in Apr. 2026 is calculated as:

ROC % (Q: Apr. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2026 ) + Invested Capital (Q: Apr. 2026 ))/ count )
=-2.048 * ( 1 - 0% )/( (1.479 + 1.588)/ 2 )
=-2.048/1.5335
=-133.55 %

where

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.571 - 1.971 - ( 1.03 - max(0, 2.886 - 2.007+1.03))
=1.479

Invested Capital(Q: Apr. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.886 - 2.143 - ( 1.846 - max(0, 3.111 - 3.266+1.846))
=1.588

Note: The Operating Income data used here is four times the quarterly (Apr. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Zeo ScientifiX's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2026  Q: Apr. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.536/( ( (0.564 + max(-1.628, 0)) + (0.609 + max(-1.411, 0)) )/ 2 )
=-0.536/( ( 0.564 + 0.609 )/ 2 )
=-0.536/0.5865
=-91.39 %

where Working Capital is:

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.063 + 0.502 + 0.412) - (1.971 + 0.634 + 0)
=-1.628

Working Capital(Q: Apr. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.276 + 0.686 + 0.458) - (2.143 + 0.671 + 0.017)
=-1.411

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Apr. 2026 )
=-3.808/12.213
=-31.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zeo ScientifiX EBIT Related Terms

Zeo ScientifiX EBIT Historical Data

* Premium members only.

The historical data trend for Zeo ScientifiX's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zeo ScientifiX EBIT Chart

Zeo ScientifiX Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.72 -8.50 -6.56 -4.61 -5.42

Zeo ScientifiX Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.37 -2.05 -0.78 -0.84 -0.13

ZEOX vs LNAI, GDTC, HOOK: EBIT Comparison

For the Biotechnology subindustry, Zeo ScientifiX's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zeo ScientifiX EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's EV-to-EBIT falls into.


ZEOX
50GF Score
Zeo ScientifiX Inc ZEOX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zeo ScientifiX EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-3.81 Mil mean?
Zeo ScientifiX (ZEOX) has a EBIT of $-3.81 Mil as of Apr. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zeo ScientifiX.
Is Zeo ScientifiX's EBIT too high?
Zeo ScientifiX's current EBIT is $-3.81 Mil. Overall, Zeo ScientifiX has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's EBIT compare to LNAI and GDTC?
Zeo ScientifiX's EBIT of $-3.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zeo ScientifiX. Zeo ScientifiX's current EBIT is $-3.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.67, compared to a current price of $1.75 — trading 34.5% below its estimated fair value. The current EBIT is $-3.81 Mil. Zeo ScientifiX's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current EBIT is $-3.81 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zeo ScientifiX (ZEOX) Overvalued in 2026?

Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued. The current stock price of $1.75 is trading 34.5% below its estimated GF Value™ of $2.67. GuruFocus considers Zeo ScientifiX to be Possible Value Trap.

Key valuation signals for ZEOX:

  • EBIT: $-3.81 Mil
  • GF Value™: $2.67 vs. price of $1.75 (34.5% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zeo ScientifiX Business Description

Address 3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
50GF Score

Get the complete analysis for ZEOX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.75
Price
$2.67
GF Value